vs
CVB FINANCIAL CORP（CVBF）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
CVB FINANCIAL CORP的季度营收约是再鼎医药的1.1倍（$133.8M vs $127.1M），再鼎医药同比增速更快（17.1% vs 8.4%），CVB FINANCIAL CORP自由现金流更多（$217.3M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs 2.8%）
CVB金融集团是一家美国银行控股公司，运营公民商业银行，主要服务加利福尼亚州市场，面向中小企业、专业机构及个人客户提供商业银行、个人银行、财富管理等多元金融服务，核心业务包含商业贷款、存款账户、资产管理等。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
CVBF vs ZLAB — 直观对比
营收规模更大
CVBF
是对方的1.1倍
$127.1M
营收增速更快
ZLAB
高出8.8%
8.4%
自由现金流更多
CVBF
多$244.0M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
2.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $133.8M | $127.1M |
| 净利润 | — | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | 55.6% | -54.6% |
| 净利率 | — | — |
| 营收同比 | 8.4% | 17.1% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $0.41 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CVBFZLAB
| Q4 25 | $133.8M | $127.1M | ||
| Q3 25 | $128.6M | $115.4M | ||
| Q2 25 | $126.4M | $109.1M | ||
| Q1 25 | $126.7M | $105.7M | ||
| Q4 24 | $123.5M | $108.5M | ||
| Q3 24 | $126.5M | $101.8M | ||
| Q2 24 | $125.3M | $100.1M | ||
| Q1 24 | $126.6M | $87.1M |
净利润CVBFZLAB
| Q4 25 | — | — | ||
| Q3 25 | $52.6M | $-36.0M | ||
| Q2 25 | $50.6M | $-40.7M | ||
| Q1 25 | $51.1M | $-48.4M | ||
| Q4 24 | — | — | ||
| Q3 24 | $51.2M | $-41.7M | ||
| Q2 24 | $50.0M | $-80.3M | ||
| Q1 24 | $48.6M | $-53.5M |
毛利率CVBFZLAB
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% | ||
| Q1 24 | — | 61.4% |
营业利润率CVBFZLAB
| Q4 25 | 55.6% | -54.6% | ||
| Q3 25 | 53.7% | -42.3% | ||
| Q2 25 | 54.4% | -50.3% | ||
| Q1 25 | 54.9% | -53.3% | ||
| Q4 24 | 55.1% | -62.6% | ||
| Q3 24 | 53.5% | -66.6% | ||
| Q2 24 | 54.9% | -76.0% | ||
| Q1 24 | 52.8% | -80.7% |
净利率CVBFZLAB
| Q4 25 | — | — | ||
| Q3 25 | 40.9% | -31.2% | ||
| Q2 25 | 40.0% | -37.3% | ||
| Q1 25 | 40.3% | -45.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | 40.5% | -40.9% | ||
| Q2 24 | 39.9% | -80.2% | ||
| Q1 24 | 38.4% | -61.4% |
每股收益（稀释后）CVBFZLAB
| Q4 25 | $0.41 | $-0.05 | ||
| Q3 25 | $0.38 | $-0.03 | ||
| Q2 25 | $0.37 | $-0.04 | ||
| Q1 25 | $0.36 | $-0.04 | ||
| Q4 24 | $0.36 | $-0.09 | ||
| Q3 24 | $0.37 | $-0.04 | ||
| Q2 24 | $0.36 | $-0.08 | ||
| Q1 24 | $0.35 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $376.4M | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.3B | $715.5M |
| 总资产 | $15.6B | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CVBFZLAB
| Q4 25 | $376.4M | $689.6M | ||
| Q3 25 | $783.9M | $717.2M | ||
| Q2 25 | $738.6M | $732.2M | ||
| Q1 25 | $529.1M | $757.3M | ||
| Q4 24 | $204.7M | $779.7M | ||
| Q3 24 | $453.5M | $616.1M | ||
| Q2 24 | $844.2M | $630.0M | ||
| Q1 24 | $949.6M | $650.8M |
股东权益CVBFZLAB
| Q4 25 | $2.3B | $715.5M | ||
| Q3 25 | $2.3B | $759.9M | ||
| Q2 25 | $2.2B | $791.7M | ||
| Q1 25 | $2.2B | $810.8M | ||
| Q4 24 | $2.2B | $840.9M | ||
| Q3 24 | $2.2B | $667.7M | ||
| Q2 24 | $2.1B | $704.2M | ||
| Q1 24 | $2.1B | $762.2M |
总资产CVBFZLAB
| Q4 25 | $15.6B | $1.2B | ||
| Q3 25 | $15.7B | $1.2B | ||
| Q2 25 | $15.4B | $1.2B | ||
| Q1 25 | $15.3B | $1.2B | ||
| Q4 24 | $15.2B | $1.2B | ||
| Q3 24 | $15.4B | $985.3M | ||
| Q2 24 | $16.2B | $987.4M | ||
| Q1 24 | $16.5B | $988.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $221.4M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $217.3M | $-26.7M |
| 自由现金流率自由现金流/营收 | 162.4% | -21.0% |
| 资本支出强度资本支出/营收 | 3.0% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $391.5M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流CVBFZLAB
| Q4 25 | $221.4M | $-26.0M | ||
| Q3 25 | $81.5M | $-32.0M | ||
| Q2 25 | $53.1M | $-31.0M | ||
| Q1 25 | $41.9M | $-61.7M | ||
| Q4 24 | $249.8M | $-55.8M | ||
| Q3 24 | $71.4M | $-26.8M | ||
| Q2 24 | $26.1M | $-42.2M | ||
| Q1 24 | $77.5M | $-90.1M |
自由现金流CVBFZLAB
| Q4 25 | $217.3M | $-26.7M | ||
| Q3 25 | $80.7M | $-35.0M | ||
| Q2 25 | $52.3M | $-33.9M | ||
| Q1 25 | $41.2M | $-63.2M | ||
| Q4 24 | $244.6M | $-58.4M | ||
| Q3 24 | $70.2M | $-28.2M | ||
| Q2 24 | $24.4M | $-42.9M | ||
| Q1 24 | $77.3M | $-91.1M |
自由现金流率CVBFZLAB
| Q4 25 | 162.4% | -21.0% | ||
| Q3 25 | 62.8% | -30.4% | ||
| Q2 25 | 41.4% | -31.1% | ||
| Q1 25 | 32.5% | -59.9% | ||
| Q4 24 | 198.0% | -53.8% | ||
| Q3 24 | 55.5% | -27.7% | ||
| Q2 24 | 19.5% | -42.9% | ||
| Q1 24 | 61.1% | -104.5% |
资本支出强度CVBFZLAB
| Q4 25 | 3.0% | 0.5% | ||
| Q3 25 | 0.7% | 2.6% | ||
| Q2 25 | 0.7% | 2.6% | ||
| Q1 25 | 0.5% | 1.5% | ||
| Q4 24 | 4.2% | 2.4% | ||
| Q3 24 | 1.0% | 1.3% | ||
| Q2 24 | 1.4% | 0.7% | ||
| Q1 24 | 0.1% | 1.1% |
现金转化率CVBFZLAB
| Q4 25 | — | — | ||
| Q3 25 | 1.55× | — | ||
| Q2 25 | 1.05× | — | ||
| Q1 25 | 0.82× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.39× | — | ||
| Q2 24 | 0.52× | — | ||
| Q1 24 | 1.59× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CVBF
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
